









Sustainability strategy of pharmaceutical business

Four strategic focus areas	Aspirational goals	Targets	Progress	SDGs
Products and services	We will create innovative, original drugs to support patients in the shortest time possible.	<p>Engaging in R&D Activities</p> <p>We will continue our efforts and investments into research and development activities of innovative drugs in specific therapeutic areas.</p>	<p>In November 2022, JW Pharmaceutical Corporation (JWP), our licensee, received approval to manufacture and market ENAROY® tablets in the Republic of Korea. In addition, phase III clinical trials for CORECTIM® Ointment 0.25% and CORECTIM® Ointment 0.5% focusing on infant patients were successfully completed. Subsequently, we set out to revise the relevant package inserts to include infants as an intended patient population, which was completed in January 2023. In 2022, we spent 29.8 billion Yen on our research and development activities.</p>	
		<p>Fostering Ethical Awareness</p> <p>In order to develop talent and foster employees' ethical awareness and sense of responsibility towards saving patients, we will continue to learn more about patients' needs by engaging in dialogue with medical experts through our internal educational activity "For the Patients Project."</p>	<p>In 2022, we carried out interviews with health professionals and representatives from healthcare venture companies and held roundtable talks among company employees who experienced atopic dermatitis, led by the 11 employees who took part in our "For the Patients Project" as facilitators.</p>	
People	We will strive to nurture talent development which enables us to create first-in-class (FIC) drugs.	<p>Community Investment*</p> <p>Between 2015 and 2030 we will invest US\$600 million to help make communities inclusive and resilient, with our employees contributing 300,000 volunteering hours.</p>	<p>Since 2015, we invested US\$450 million in our communities and employees volunteered 193,521 hours on company time.</p>	  
		<p>Greenhouse Gas Emissions*</p> <p>By 2030, we will reduce emissions from our own operations (Scope1 & 2) by 47% and emissions associated with purchased goods and services (Scope3 Category1) by 28%, against a 2019 base year.</p>	<p>Scope 1 & 2 GHG emissions: -16% Scope 3 GHG emissions associated with purchased goods and services: -11%</p>	 
Product safety and responsibility	We will strictly comply with all relevant laws, regulations, and industry standards in order to deliver safe drugs to patients.	<p>Responsible Promotion of Drugs</p> <p>We will conduct, among others, regular training programs for our medical representatives in order to provide medical professionals with latest, appropriate information on pharmaceutical products.</p>	<p>After their initial training, all of our Medical Representatives take a mandatory e-learning course once a month to keep their skills and knowledge up-to-date.</p>	

* Target for Community Investment and Greenhouse Gas Emission are Group-wide targets.